You searched for "procedures"

4121 results found

Management of giant retinal tears with vitrectomy and perfluorocarbon liquid postoperatively as a short-term tamponade

The authors report an eight year retrospective case series study of 30 eyes of 29 patients with who underwent a giant retinal tear-related retinal detachment repair. M: F ratio was 23:6. Right to left eye ratio was 16:14. The mean...

A standardised strategy for uveitis etiological diagnosis

This was a prospective, non-inferiority, multicentre randomised control trial, which aimed to assess the effectiveness of a standardised approach in the etiological diagnosis of uveitis versus an open strategy, where clinicians could perform any test. The authors developed their standardised...

Protecting retinal ganglion cells

Glaucoma is considered to be a heterogeneous group of conditions giving retinal ganglion cells (RGC) damage. Lowering intraocular pressure (IOP) reduces the risk of progressive RGC loss in glaucoma. Regeneration of the optic nerve has been shown to restore some...

Licence to save: a UK survey of anti-VEGF use for the eye

This comment article highlights the controversy that exists in the choice for anti-VEGF drugs used for treatment of macular oedema and wet age-related macular degeneration (AMD). Two existing licensed drugs for macular oedema are ranibizumab (Lucentis) and aflibercept (Eylea). A...

Prediction errors of formulas in optical biometers

This study was conducted retrospectively in a private practice setting. Nine formulas were compared for prediction error (postoperative spherical equivalent (SE) minus, predicted SE calculated by each formula), using two optical biometers (Lenstar – optical low coherence reflectometry (OLCR) and...

Leber’s hereditary optic neuropathy: from lab to clinic

Leber’s hereditary optic neuropathy (LHON) was the first clinically described mitochondrial disorder (1871). This article reviews the pathophysiology and clinical features of LHON with a focus on translational research. G11778A is currently the most common mutation worldwide and is associated...

Intravitreal afibercept and ranibizumab for PCV

This is a retrospective, interventional series comprising 98 eyes with polypidal choroidal vasculopathy (PCV) with the aim of comparing treatments with afibercept and ranibizumab, highlighting any differences in their efficacy. Case notes and imaging (FFA / ICG / OCT) were...

25-gauge PPV for retained lens fragments

This was a retrospective study including 40 eyes of 40 patients with mean age of 78 years, 19 females and 21 males, who underwent 25-gauge pars plana vitrectomy (PPV) for retained lens fragments with a minimum of six months of...

Comparison of retinal pigment epithelium-choroid graft surgery and anti-VEGF therapy in patients with wet AMD

This was a randomised intervention study in wet AMD patients to investigate benefits of free RPE-choroid graft transplantation surgery versus (continuation of) anti-VEGF treatment. Twenty patients who met the inclusion criteria were subdivided into three subgroups, i.e. RPE tears involving...

Stereotactic radiotherapy for polypoidal choroidal vasculopathy

Polypoidal choroidal vasculopathy (PCV) is a variant of neovascular AMD. It is a disease of choroidal vasculature characterised by abnormal branching vascular network with aneurysmal dilatations (polyps). Features of PCV include pigment epithelial detachments (PED), subretinal fluid (SRF) accumulation and...

Does paediatric uveitis reactivate after treatment with anti-TNF-a drugs?

As a potentially blinding disease that can affect 7-27/100000 children, uveitis remains a rare condition, where little evidence based data is available to guide management decisions. Most paediatric uveitis cases are chronic, anterior and non-infectious and may be associated with...

RaScaL Study

The RaScaL study was a six month, single-centre, controlled, prospective phase I/II study in which subjects with diabetic macular oedema (DME) and associated peripheral nonperfusion on ultrawide-field fluorescein angiography (UWFA) were randomised to: (1) study arm: ranibizumab (0.5 mg) injection...